Clinical Trial Update: XP13512 (Gabapentin Enacarbil) Extension Study in Patients With Restless Legs Syndrome. [Phase 3]

View source ↗

Summary

Extension phase 3 trial of XP13512 (gabapentin enacarbil) in patients with Restless Legs Syndrome; the study has completed and results were posted in 2011.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Restless Legs Syndrome

Drugs mentioned

• XP13512 (Gabapentin Enacarbil) (gabapentin enacarbil)

Snippet

Sponsor: XenoPort, Inc. | Conditions: Restless Legs Syndrome | Phase 3 | Status: COMPLETED | Results posted: 2011-06-23